Overview

Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The two objectives of this study were to evaluate long-term efficacy and safety of adalimumab treatment in participants who had moderate to severe chronic plaque psoriasis and to evaluate the effectiveness of adalimumab retreatment in participants who had therapeutic response to adalimumab and were then withdrawn from adalimumab treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Abbott
Treatments:
Adalimumab